Search by Drug Name or NDC
NDC 00135-0400-01 ABREVA 200; 40 mg/g; mg/g Details
ABREVA 200; 40 mg/g; mg/g
ABREVA is a TOPICAL GEL in the HUMAN OTC DRUG category. It is labeled and distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. The primary component is GLYCERIN; LIDOCAINE HYDROCHLORIDE.
Product Information
| NDC | 00135-0400 |
|---|---|
| Product ID | 0135-0400_65bd242f-4c6a-436c-8ec0-7b2e0d73ed9d |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | ABREVA |
| Proprietary Name Suffix | Rapid Pain Relief |
| Non-Proprietary Name | glycerin, lidocaine |
| Product Type | HUMAN OTC DRUG |
| Dosage Form | GEL |
| Route | TOPICAL |
| Active Ingredient Strength | 200; 40 |
| Active Ingredient Units | mg/g; mg/g |
| Substance Name | GLYCERIN; LIDOCAINE HYDROCHLORIDE |
| Labeler Name | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| Pharmaceutical Class | Allergens [CS], Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Cell-mediated Immunity [PE], Glycerol [CS], Increased Histamine Release [PE], Increased IgG Production [PE], Local Anesthesia [PE], Non-Standardized Chemical Allergen [EPC] |
| DEA Schedule | n/a |
| Marketing Category | OTC MONOGRAPH FINAL |
| Application Number | part347 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00135-0400-01 (00135040001)
| NDC Package Code | 0135-0400-01 |
|---|---|
| Billing NDC | 00135040001 |
| Package | 1 TUBE in 1 PACKAGE (0135-0400-01) / 3 g in 1 TUBE |
| Marketing Start Date | 2023-06-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |